Uses
YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
Source: US FDA prescribing information
Molecule
Cantharidin
Available on request
- Presentations
- 1
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Cantharidin is a prescription medicine indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. It is available as topical solution. MedsAcross supplies Cantharidin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- US FDA first approval
- 21 July 2023
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Topical
- Dosage forms
- Topical solution
- Identifiers
- UNII IGL471WQ8PRxCUI 1984CAS 56-25-7DrugBank DB12328Q410884
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
The mechanism of action of cantharidin in the treatment of molluscum contagiosum is unknown.
Source: US FDA prescribing information
Dosing overview
All healthcare professionals should receive instruction and training prior to preparation and administration of YCANTH. For topical use only. Not for oral, mucosal, or ophthalmic use. Apply a single application directly to each lesion every 3 weeks as needed. Do not use more than two applicators during a single treatment session. Remove with soap and water 24 hours after treatment. For additional instructions on preparation and administration of YCANTH, see Full Prescribing Information.
Source: US FDA prescribing information
Contraindications
None None
Source: US FDA prescribing information
Warnings and precautions
Toxicities Associated with Inappropriate Administration: Life threatening or fatal toxicities can occur if administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes. Local Skin Reactions: Reactions at the application site have included vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to 24 hours after treatment. Flammability: YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.
Source: US FDA prescribing information
Side effects
The following adverse reactions are described elsewhere in the labeling: Local Skin Reactions Most common (incidence ≥1%) adverse reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions are expected and should be reported if they are severe.
Source: US FDA prescribing information
Storage
Store at 20°C to 25°C (68° to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F), protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
1 presentations of Cantharidin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ycanth 3.2 mg/0.45 mL topical solutionTopical | Verrica Pharmaceuticals | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 21 July 2023 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Cantharidin in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Cantharidin available for export from India?
Yes, on request. MedsAcross lists 1 presentations of Cantharidin and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Cantharidin have?
The catalogue lists 1 brand names for Cantharidin, including Ycanth.
Is Cantharidin approved by the US FDA?
Yes. The US FDA first approved Cantharidin on 21 July 2023, according to Drugs@FDA.
Does Cantharidin need cold chain shipping?
No listed presentation of Cantharidin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
References
- YCANTH prescribing information (Verrica Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 13 November 2024
Request Cantharidin for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.